KDM1A/LSD1 inhibition enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer
We examined global transcriptional changes in ES2-control and ES2-KDM1A knockout (KO) cells that are treated with vehicle or estrogen receptor beta agonist LY500307 using RNA-sequencing. Overall design: ES2-control and ES2-KDM1A knockout cells were treated with vehicle or LY500307 (5 µM) for 48 hours. Total RNA was isolated using RNeasy mini kit according to the manufacturer's instructions (Qiagen, Valencia, CA).  Illumina TruSeq RNA Sample Preparation was performed following the manufacturer's protocol. Samples were run on an Illumina HiSeq 3000 in duplicate. The combined raw reads were aligned to UCSC hg19 by Tophat2. Genes were annotated and quantified by the HTSeq-DESeq pipeline.